Hadassah

Hadassah Drug to Fight Fatty Liver Disease Progressing Well in US Clinical Trials

Thursday, Sep 3 2015

Clinical trials with a Hadassah-developed technology to treat fatty liver disease are moving forward in 25 medical centers, in the United States and Australia. Fatty liver disease, in its severe form—called non-alcoholic steatohepatitis (NASH)—can lead to cirrhosis and liver cancer and there are currently no other treatments available.

Among the US test sites are the Cleveland Clinic (Ohio), Duke Liver Center (Durham, NC), Baylor St. Luke's Medical Center (Houston, Tex), and University of Virginia (Charlottesville). The Australian sites include Westmead Hospital (Sydney) and The Alfred (Melbourne).

Hadasit, Hadassah’s technology transfer arm, and Immuron, an Australian biopharmaceutical company, worked together to develop the product, being referred to as IMM-124E. The collaborative effort combines Hadassah’s oral immune modulation approach with antibodies produced by Immuron. See http://www.hadassah.org/news-stories/fda-grants-approval-for-us.html

Immuron has also announced that it is beginning a United States Investor Roadshow, where it will showcase its technology platform and profile to US investment groups. The company reports that its clinical trials “are progressing well” and that “a recent Deutsche Bank review of the NASH market suggests that there is a worldwide market for NASH of between $35-40 billion.” The company further explains that “the high prevalence of Type 2 diabetes and obesity, which leads to NASH and other non-alcoholic fatty liver diseases, boosts the prevalence of NASH and its market growth.”

View the Roadshow presentation: http://www.immuron.com/index.php/download_file/-/view/142/

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Sep 21 2018

Hadassah Numbers to Commend and Celebrate

Over the past year, Hadassah Medical Center researchers received over 60 percent of the National Science Foundation Awards for biomedical research in Israeli hospitals...

READ MORE ›
alt_text

Thursday, Sep 20 2018

NanoKnife® Technology to Treat Prostate Cancer Comes to Hadassah

NanoKnife® technology, the most innovative method for treatment of localized prostate cancer, is now being applied at the Hadassah Medical Organization, making Hadassah the first in Israel to treat prostate cancer in this minimally invasive way.

READ MORE ›
alt_text

Thursday, Sep 20 2018

Car-ramming Victim and His Family Give Thanks

Life in the Horaling family changed forever on November 17, 2017. Dad Ebenezer Horaling, 35, was taking a bus to work as a custodian at a boys’ junior high school 20 minutes away from his home. Ebenezer had gotten off the bus and was walking to the school when a 17-year-old terrorist drove into him, throwing him into the air.

READ MORE ›
alt_text

Thursday, Sep 20 2018

Hadassah Director General Organizes Surprise for Hospitalized Children

Providing a respite from medical treatment during this holiday season, a collection of antique cars suddenly appeared on the lawns of Hadassah Hospital Ein Kerem, and the hospitalized children and their families were invited to take a close look.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More